Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 125, Issue 9, Pages 2122-2126Publisher
WILEY
DOI: 10.1002/ijc.24602
Keywords
acromegaly; somatostatin analogs; ZAC1; resistance; tumor shrinkage
Categories
Funding
- Deutsche Forschungsgemeinschaft [TH 901/1-3]
- Novartis Pharma GmbH
Ask authors/readers for more resources
Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-associated growth hormone secreting pituitary tumors. Although a good portion of acromegalic patients gets normalized after SSA treatment, strict hormonal control Is not achieved in a sizeable proportion of these patients. The reasons for this incomplete response to SSA treatment are unclear. We have found that the tumor suppressor ZAC1 (LOT1/PLAGL1) is essential for the anti proliferative effect of SSA in pituitary tumor cells. The aim of the present retrospective cohort study was to determine whether ZAC1 immunoreactivity in archival somatotrophinoma tissue derived from 45 patients with acromegaly routinely pretreated with SSA before surgery, was associated with response to SSA (normalization of GH, IGF-1 and presence of tumor shrinkage). All tumors displayed ZAC1 immunoreactivity [weak (+; n = 15), moderate (+ +; n = 16) and strong (+ + +; n = 14)]. A significant positive correlation was found between strong ZAC1 immunoreactivity and IGF-1 normalization and presence of tumor shrinkage after SSA treatment, which was not affected by age at diagnosis, gender or duration of SSA treatment. These in vivo data combined with the antiproliferative properties of ZAC1/Zac1 provide evidence of a mechanistic role for this transcription factor on SSA induced tumor shrinkage and hormone normalization. (C) 2009 UICC
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available